AUTHORS
Murugan Selvam, PhD, Shaivi Laveti, MS2, Leslie Martinez-Gutierrez, MS3, Tishira Shah, MS4, Emily Mackey, DVM PhD5, Daniel Alvarado, BS6, Marianna Giorgi, BE7, Jennifer Peresie, BS8, Pamela J. Sung, MD PhD9
AFFILIATIONS
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Acute myeloid leukemia (AML) is a complex hematologic malignancy marked by the clonal expansion of immature myeloid progenitor cells or blasts. De novo AML patients often have activating mutations in FLT3, including FLT3-ITD in about 25%. FLT3 inhibitors are used for treating all stages of FLT3+ AML patients. Pre-clinical mouse models are essential for recapitulating disease pathogenesis and evaluating novel therapeutic strategies. However, current AML animal models often rely on transplantation into immunocompromised or irradiated recipient mice, limiting the contribution of the native immune system and tumor microenvironment, which may impact their ability to faithfully model therapeutic responses in human AML. In mouse models, Flt3-ITD alone results in MPN and is insufficient to induce AML. In patients, FLT3-ITD frequently co-occurs with mutations in NPM1 and DNMT3A. Notably, DNMT3A mutations co-occur in 35% of FLT3-ITD AML patients. A well-characterized mouse model Flt3 ITD/ITD Dnmt3a fl/fl Mx1::Cre (Meyer 2016) presents several limitations, including spontaneous AML induction, early lethality precluding treatment of primary AML mice, and breeding challenges.
To address these issues, we developed a tamoxifen (TAM)-inducible mouse model by replacing Mx1::Cre with Rosa26::ERT2-Cre for pre-clinical studies of AML in immunocompetent mice with a native marrow microenvironment and a common genetic profile of human AML. The resulting mice are homozygous for Flt3-ITD, Dnmt3a fl, and Rosa26::ERT2-Cre (FDR), which simplifies the breeding and yields 100% mice with the AML genotype. Mice were treated for 6 doses of TAM over 2 weeks. CBCs showed development of marked leukocytosis with TAM vs. control. Blood films and flow demonstrated myeloproliferation with increased Kit+ cells starting at 6 weeks, consistent with progressive development of AML. Median survival of TAM mice was 9.3 weeks vs. NR for control (p=0.0025). Flow analysis demonstrated that the cellular phenotype of TAM-treated mice largely resembles the Mx1::Cre model with differences most notable in the LSK subsets. Whereas the Mx1::Cre LSKs were primarily restricted to MPP3/4, the FDR LSKs had more MPP2, ST-HSCs, and LT-HSCs. Histology revealed extensive leukemic infiltration in the spleen and bone marrow (BM). BM morphology was consistent with an AML with maturation with 69% immature cells. Strikingly, extensive central nervous system (CNS) involvement was also observed. Transplantation of Lin- splenic leukemia cells into CD45.1+ healthy recipients was fully-penetrant and exhibited aggressive leukemic infiltration in peripheral organs and similar CNS involvement. Secondary mice were moribund by 3.5 weeks post-transplant. BM morphology was consistent with an AML without maturation with 85% immature cells. Flow cytometry of spleen and BM from 2° mice showed similar distribution of the LSK population as the primary AML model.
To evaluate the utility of the 1o model for preclinical drug testing, TAM-induced FDR mice were treated with vehicle or gilteritinib (gilt) for 4 weeks. Gilt reduced leukemic burden, decreased the Kit+ population, promoted myeloid differentiation, and significantly increased survival compared to control. While 4 weeks of treatment was sufficient to substantially reduce spleen size in prior studies, spleen size was not reduced in this model, potentially due to the contribution of the native microenvironment on FLT3 inhibitor resistance. We characterized Flt3 WT, Dnmt3a fl, and Rosa26::ERT2-Cre homozygous (DR) mice as additional control and as expected, DR mice treated with TAM did not develop AML or other overt phenotype. We also generated Flt3-ITD, Dnmt3a WT, and Rosa26::ERT2-Cre homozygous (FR) mice to further investigate the requirement of Dnmt3a loss vs. Cre associated effects in Flt3-ITD driven leukemogenesis (Straube 2023). Characterization of the FR mice model is underway and will be updated at the meeting. Overall, the FDR AML model offers a fully inducible, genetically defined, and highly reproducible immunocompetent system for modeling FLT3-ITD AML for pre-clinical therapy development and can provide valuable insights into leukemic progression and CNS infiltration.
DISCLOSURES
Murugan Selvam, PhD: No relevant conflicts of interest to declare.